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ABSTRACT
Objective: To assess the frequency of calcinosis in patients with juvenile dermatomyositis, and the possible risk factors 
for that manifestation. Methods: Medical record review of 34 patients, with an emphasis on the following characteristics: 
demographic, clinical and laboratory data; type of treatment; adherence to treatment; disease course (monocyclic, chronic 
and polycyclic); and disease severity. Patients were divided into two groups as follows: those who developed calcinosis 
(up to the sixth month of follow-up and after six months of follow-up) and those who did not develop calcinosis. Twenty-
seven patients underwent two nailfold capillaroscopies (NFC), which were considered altered when the scleroderma 
pattern was found. Results: The mean age of symptom onset of the 34 patients was 6.5 years, the time until diagnosis 
was 1.2 years, and 70% were females. Half of the patients had a monocyclic disease course, and only 14.7% had severe 
vasculitis. Almost 90% of the patients undergoing NFC showed a change on the fi rst assessment, 74% showed a change 
on the second assessment, and the mean interval between both assessments was 1.6 year. Calcinosis was evidenced in 
16 (47.1%) patients. No association was observed between the variables analyzed and the development of calcinosis. 
Conclusion: No risk factors for calcinosis were identifi ed in this study, although that complication was found in half of 
the patients with juvenile dermatomyositis studied. 
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INTRODUCTION
Juvenile dermatomyositis (JDM) is a multisystemic disease, 
part of a heterogeneous group of acquired inflammatory 
muscle disorders, and corresponds to 85% of all idiopathic 
infl ammatory myopathies in children.1 It is characterized by 
vasculitis, which affects primarily the skin and muscles,2,3 
but can also affect other organs, such as the heart, lung, and 
gastrointestinal tract.2 
The fi ve diagnostic criteria originally proposed by Bohan 
and Peter4,5 in 1975 have remained as the standard criteria for 
diagnosing JDM, considering the onset age up to 18 years. 
However, a number of pediatric rheumatologists consider that 
the diagnosis of JDM in most patients does not require meeting 
four of the fi ve criteria.6
Nailfold capillaroscopy (NFC) is a complementary test that 
helps diagnosing JDM and assessing disease activity.7 
Despite the advances in therapy, JDM remains associated 
with signifi cant morbidity. In several studies, a signifi cant per-
centage of patients has persistently active disease, develops cal-
cinosis, and undergoes a signifi cant delay in statural growth.8–12
Calcinosis is more common in the pediatric population, 
affecting 10%–70% of the children and adolescents with JDM, 
as compared with 30% of the adults.6,12–15 Although most of the 
calcinosis cases develop in the fi rst three years after diagnosis, 
it can appear in up to 20 years after disease onset.16 
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The presence of calcinosis is associated with a delay in 
diagnosis, longer time of untreated disease, chronic course, 
disease severity, and inadequate therapy or resistance to 
treatment.9
This study aimed at assessing the frequency of calcinosis 
in patients with JDM, in addition to assessing possible risk 
factors for that manifestation.
MATERIAL AND METHODS 
According to the criteria of Bohan and Peter,4,5 57 patients 
were diagnosed with either defi nitive JDM (presence of typical 
cutaneous lesions associated with three of the other criteria) 
or very probable JDM (presence of typical cutaneous lesions 
associated with two of the other criteria), being followed up 
at the Pediatric Rheumatology sector from 1992–2010. Of the 
57 patients, 23 with incomplete data were excluded. Patients 
with overlapping syndrome were not included in the study.
A retrospective analysis was performed based on the 
medical record review of 34 patients, with an emphasis on 
the following characteristics: demographic, clinical and 
laboratory data; type of treatment (corticosteroids and other 
immunosuppressive drugs); adherence to treatment; course of 
the disease (monocyclic, chronic and polycyclic); severity of 
disease; and changes observed in NFC. Adherence to therapy 
was considered good in the presence of at least 80% agree-
ment between the treatment prescribed by the physician and 
that performed by the patient, according to the defi nition used 
by the World Health Organization.17 The disease course was 
defi ned as follows: monocyclic, when the patients underwent 
disease remission two years after its onset; polycyclic, in the 
presence of one or more relapses after disease remission; and 
chronic, when symptoms persisted for over two years.18 The 
severity of vasculitis was defi ned as the presence of persistent 
vasculitic lesions unresponsive to usual treatment, cutaneous 
ulcerations, intestinal vasculitis, or need for intravenous im-
munoglobulin, thalidomide or cyclophosphamide.
Initially, the patients were divided into two groups as 
follows: those who had calcinosis and those who had no 
calcinosis during the course of disease until the end of the 
study. Later, the calcinosis group was assessed separately as 
follows: patients developing calcinosis within the fi rst six 
months of follow-up in the outpatient clinic or those who 
already had calcinosis prior to beginning the follow-up in 
the outpatient clinic (initial calcinosis); and patients who 
developed calcinosis after six months of follow-up in the out-
patient clinic (progressive calcinosis). Twenty-seven patients 
underwent NFC at disease onset and during its course, by use 
of an optical microscope with 10x and 16x magnifi cations. 
The following parameters were assessed on NFC: number of 
capillaries per millimeter; presence and intensity of capillary 
deletion; and presence of ectatic, bushy, entangled, or giant 
capillaries. The scleroderma (SD) pattern was defi ned as the 
presence of capillary deletion associated with capillary ectasia 
and⁄or giant capillaries.19 The NFC was considered altered 
when the SD pattern was present.
To assess the association between qualitative variables, the 
chi-square test or the Fisher exact test was used. The Student 
t test, Mann-Whitney test and Kruskal-Wallis test were used 
for comparison between the groups.
RESULTS 
Some features of the 34 patients assessed were as follows: 
mean age at symptom onset, 6.5 ± 3.9 years; mean time 
until diagnosis, 1.2 ± 2.0 years; mean disease duration, 
5.8 ± 3.6 years; and mean outpatient clinic follow-up time, 
4.0 ± 2.8 years (Table 1).
Of the 34 patients studied, 24 (70.6%) were females and 
22 (64.7%) were Caucasoid. The disease course was as fol-
lows: monocyclic, 17 patients (50%); chronic, 11 (32.4%); 
and polycyclic, six (17.6%). Disease intensity was severe in 
only fi ve (14.7%) patients, and cutaneous ulcers were present 
in four (11.7%).
Twenty-seven patients underwent NFC at disease onset 
and during its course, with a mean interval of 1.6 year between 
Table 1
Epidemiological and clinical data of patients with juvenile 
dermatomyositis (n = 34)
Mean age at symptom onset (years) 6.5 ± 3.9
Mean time until diagnosis (years) 1.2 ± 2.0
Mean disease duration (years) 5.8 ± 3.6
Mean follow-up time (years) 4.0 ± 2.8
Monocyclic course, n (%) 17 (50)
Chronic course, n (%) 11 (32.4)
Polycyclic course, n (%) 6 (17.6)
Severe vasculitis, n (%) 5 (14.7)
Altered initial NFC, n (%) 24 (88.9)
Altered ﬁ nal NFC, n (%) 20 (74.1) 
Calcinosis, n (%) 16 (47.1)
Initial calcinosis, n (%) 6 (17.6)
Calcinosis on follow-up, n (%) 10 (29.4)
High frequency of calcinosis in juvenile dermatomyositis: a risk factor study 
547Rev Bras Reumatol 2012;52(4):545-553
both NFC. Of those 27 patients, 24 (88.9%) had an altered 
initial NFC, with 91.7% of these patients showing active 
disease at the time of the exam, and 20 (74.1%) had an al-
tered NFC during disease course, with 70% of these patients 
showing active disease at the time of the exam.
Calcinosis was identifi ed in 16 (47.1%) patients at the 
initial exam and/or during follow-up, with a mean time of 
development after the diagnosis of 2.5 ± 1.9 years (six patients 
had initial calcinosis, and 10 patients had it during disease 
course). Of those 16 patients, fi ve (31.3%) were 3 years of age 
or younger, but showed no statistical difference as compared 
with the older patients (P = 0.317).
The following parameters showed no association with 
the development of calcinosis: demographic and clinical fea-
tures; vasculitis intensity; elevation in muscle enzymes; use 
of immunosuppressive drugs; adherence to treatment; and 
NFC changes (Table 2). When assessing separately patients 
with initial calcinosis, patients developing calcinosis during 
follow-up, and patients without calcinosis, no statistic dif-
ference between the variables was identifi ed, except for the 
monocyclic course, which was statistically more frequent in 
the group without calcinosis (P = 0.036).
In the 27 patients undergoing NFC, no association was 
found between the presence of calcinosis and changes in 
initial NFC or in NFC during disease course (P = 0.681 and 
P = 0.432, respectively). 
Of the 16 patients with calcinosis, seven had a chronic 
disease course and nine had a monocyclic or polycyclic course. 
Chronic disease course showed no association with calcinosis 
frequency and duration and age of calcinosis appearance dur-
ing disease course (P = 0.336; 0.144 and 0.374, respectively) 
(Table 3).
Table 2 
Relationship between the variables studied and the presence or absence of calcinosis in patients with juvenile dermatomyositis 
(n = 34)
Presence of calcinosis (n = 16) Absence of calcinosis (n = 18) P
Female gender, n (%) 10 (62.5) 14 (77.8) 0.329
Caucasoid, n (%) 11 (68.7) 11 (61.1) 0.642
Mean age of onset in years (SD) 6.3 (3.8) 6.7 (4.1) 0.911
Mean time until diagnosis in years (SD) 1.9 (2.7) 0.6 (0.9) 0.990
Mean disease duration in years (SD) 6.5 (3.5) 5.3 (3.7) 0.870
Mean follow-up time in years (SD) 2.8 (2.4) 5.0 (2.9) 0.553
Disease course (mono-M, poly-P, chronic-C) 6M, 3P, 7C 11M, 3P, 4C 0.336
Severe vasculitis, n (%) 3 (18.8) 2 (11.1) 0.530
Use of immunosuppressive drugs, n (%) 15 (93.7) 13 (72.2) 0.100
Adherence to treatment, n (%) 9 (56.2) 13 (72.2) 0.331
Mean time for calcinosis to develop in years (SD) 2.6 (1.7) —
Total 16 18
Table 3
Association of the type of juvenile dermatomyositis course 
with frequency and duration of calcinosis and age of calcinosis 
appearance during disease course
Monocyclic Polycyclic Chronic P
Frequency of 
calcinosis, n (%) 6 (37.5) 3 (18.7) 7 (43.7) 0.336
Mean calcinosis 
duration in years (SD) 2.8 (1.8) 3.1 (1.9) 2.6 (1.7) 0.144
Mean age of calcinosis 
appearance during disease 
course in years (SD)
9.2 (4.8) 8.0 (4.6) 8.9 (4.4) 0.374
DISCUSSION 
This study showed a high frequency of calcinosis in patients 
with dermatomyositis, although the risk factors for the devel-
opment of that late complication were not found. The mean 
time interval between symptom onset and diagnosis was 
signifi cantly greater in our patients than that reported in most 
studies,8,15,20–22 which might have resulted from the delay in 
referring patients in our study to the specialist, as we have 
already reported.23
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Half of our patients had a monocyclic disease course, while 
in the study by Huber et al.,8 37% had a monocyclic course 
and 63% had either a polycyclic or chronic course. However, 
those authors have defi ned the monocyclic course as when the 
patient had no disease activity and was not on medication for 
up to 24 months after the diagnosis, which differed from our 
defi nition, since we did not consider medication use.18 Some of 
those patients might have initiated their diseases prior to their 
parents’ perception, and, thus, had no truly monocyclic courses.
In our case series, cutaneous ulcers were observed in 11.7% 
of the patients during disease course, similarly to the frequency 
reported by Sallum et al.,12 but lower than those reported in 
other studies.6,21 The presence of cutaneous ulcers refl ects 
greater disease severity.
Nailfold capillaroscopy is an important tool to help both 
the diagnosis and the follow-up of patients with JDM. Some 
studies have reported a change in the NFC of patients with 
JDM, evidencing the SD pattern in 60% of them.24 Our pa-
tients showed an agreement between disease activity and FNC 
changes, both initially and during disease course. Other studies 
have also correlated FNC changes with disease activity.7 
Almost half of the patients had calcinosis during disease 
course, a percentage higher than that reported in most stud-
ies on JDM.6,8,11,15,21,22,25–27 One possible explanation for the 
elevated incidence of calcinosis in our population is the delay 
in diagnosis, and, thus, a longer duration of disease activity. 
The disease course in patients without calcinosis was suf-
fi ciently long for the appearance of calcinosis, allowing us to 
characterize those patients as non-candidates to the appearance 
of that complication. Calcinosis is known to result from per-
sistent disease activity, poor treatment adherence, and therapy 
refractoriness.3,9,22,28 It is worth emphasizing that calcinosis 
manifested in 10 patients during disease course even after six 
months of beginning therapy and in patients with good adher-
ence to treatment, and no association was observed between 
non-adherence and the appearance of that complication. The 
association of age and higher frequency of calcinosis has nei-
ther been reported in other studies, nor found in ours.
Despite the high frequency of calcinosis, no risk factors for 
that complication was evidenced in our study. While some stud-
ies6,8 have found no association between calcinosis and time 
until diagnosis, others11,22 have reported a higher frequency of 
calcinosis in patients with a longer time until diagnosis, and, 
consequently, a longer time until the beginning of treatment. 
Another study has reported that early treatment with high doses 
of corticoid was predictive for not developing calcinosis.9 Some 
studies have assessed the relationship between disease course 
and the presence of calcinosis, but have found no association.6,8 
In our study, 11 of the 17 patients with a monocyclic disease 
course did not develop calcinosis, suggesting that a better 
prognosis might be associated with the lower frequency of that 
complication. In contrast, chronic infl ammatory disease might 
have predisposed to its development. However, in our study, a 
higher frequency of calcinosis was not observed in any of the 
disease courses. The use of more than one immunosuppressive 
agent has been associated with the development of calcinosis 
in the study by Sallum et al.,26 showing that calcinosis is as-
sociated with most severe disease. 
This study is important, because it showed the presence 
of calcinosis in half of the patients with JDM. Nevertheless, 
we could not demonstrate the presence of risk factors for the 
development of that complication. Sample size was a limiting 
factor. Outcome and occasionally multicenter studies might 
solve that problem. To our knowledge, no studies assessing 
the association between calcinosis and NFC changes have 
been published.
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